All News

Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.

As a cancer survivor, I am always on my toes.

Should patients be given a choice on how they wish to receive bad news? One survivor seems to think so.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

From the 9/11 Victim Compensation Fund to the untimely passing of an inspirational Olympic runner, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

How the company of a puppy provided the right amount of post-trauma comfort to help navigate in a post-cancer world.

The remarks posted by patients with cancer on the Internet can be skewed. Here are four tips to keep in mind when researching your condition and treatment options.

Like opposing wind fronts my emotions collided, spinning off a funnel of survivor guilt on a day I never thought would come.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

Just as we tell the person that we love enduring cancer that they are not alone, as caregivers, neither are we.

Here are three things I learned to avoid when recovering from cancer treatment.

The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

Researchers determined that having difficulty performing at least one instrumental activity of daily living puts older patients at risk of death, unplanned hospitalization and emergency department visits.

Making the choice to get busy living is often difficult for those with cancer, but the choice to start living your best life can be a good one. Each person must decide what that life looks like and when it’s time to start living it.

Evading the cancer issue is much easier.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

Why are men more likely to discover their breast cancer later than women?

In some cases, choosing the mundane can be life-giving, help salve emotional hurts and anchor our lives.

Recent study findings show no significant difference in treatment efficacy or overall survival between men and women.

Faith can be a tricky thing when you are dealing with cancer.

In a talk to people affected by melanoma, Michael McGrady described reassessing his values after cancer and how it changed the course of his life.

There is value in information being shared from survivor to survivor. Many health issues may be common, but you can feel alone if you are not aware of them. A well-moderated online support group may be a great place to gain knowledge and comfort.

Compared with single-agent therapy, the combination of Yervoy and Opdivo showed a 38% overall response rate.

We've got a sneak peek at what’s inside CURE®'s spring issue.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

Isn’t everyone a survivor from the time of diagnosis to the end? One reader thinks so.